(Q46157399)

English

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy

scientific article published on 19 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

1 reference

based on heuristic

inferred from title

author name string

A Vazquez-Martin

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

C Oliveras-Ferraros

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

S del Barco

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

B Martin-Castillo

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

J A Menendez

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

publication date

19 January 2009

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

Annals of Oncology

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

20

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

592-595

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN758

21 January 2018

Identifiers

10.1093/ANNONC/MDN758

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/19153119

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46157399&oldid=2095273994"